Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25326896)

  • 21. Expression and clinicopathological significance of Mel-18 mRNA in colorectal cancer.
    Tao J; Liu YL; Zhang G; Ma YY; Cui BB; Yang YM
    Tumour Biol; 2014 Oct; 35(10):9619-25. PubMed ID: 24964959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancer of Zeste Homolog 2 in Colorectal Cancer Development and Progression.
    Bremer SCB; Conradi LC; Mechie NC; Amanzada A; Mavropoulou E; Kitz J; Ghadimi M; Ellenrieder V; Ströbel P; Hessmann E; Gaedcke J; Bohnenberger H
    Digestion; 2021; 102(2):227-235. PubMed ID: 31694013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
    Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
    Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ.
    Yu H; Simons DL; Segall I; Carcamo-Cavazos V; Schwartz EJ; Yan N; Zuckerman NS; Dirbas FM; Johnson DL; Holmes SP; Lee PP
    PLoS One; 2012; 7(12):e51239. PubMed ID: 23251464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer.
    Tamagawa H; Oshima T; Numata M; Yamamoto N; Shiozawa M; Morinaga S; Nakamura Y; Yoshihara M; Sakuma Y; Kameda Y; Akaike M; Yukawa N; Rino Y; Masuda M; Miyagi Y
    Eur J Surg Oncol; 2013 Jun; 39(6):655-61. PubMed ID: 23523318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
    Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.
    Wang J; Ren Y; Guo X; Cheng H; Ye Y; Qi J; Yang C; You H
    Mol Med Rep; 2015 May; 11(5):3585-92. PubMed ID: 25571919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2.
    Lin L; Zheng Y; Tu Y; Wang Z; Liu H; Lu X; Xu L; Yuan J
    Hum Pathol; 2015 Jul; 46(7):971-80. PubMed ID: 25907866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
    Cao W; Ribeiro Rde O; Liu D; Saintigny P; Xia R; Xue Y; Lin R; Mao L; Ren H
    PLoS One; 2012; 7(12):e52984. PubMed ID: 23300840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of EZH2 expression is associated with the proliferation, apoptosis, and migration of SW620 colorectal cancer cells in vitro.
    He SB; Zhou H; Zhou J; Zhou GQ; Han T; Wan DW; Gu W; Gao L; Zhang Y; Xue XF; Zhang LF; Fei M; Hu SQ; Yang XD; Zhu XG; Wang L; Li DC
    Exp Biol Med (Maywood); 2015 Apr; 240(4):458-66. PubMed ID: 25005166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches.
    D'Angelo V; Iannotta A; Ramaglia M; Lombardi A; Zarone MR; Desiderio V; Affinita MC; Pecoraro G; Di Martino M; Indolfi P; Casale F; Caraglia M
    J Exp Clin Cancer Res; 2015 Aug; 34(1):83. PubMed ID: 26268310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genome-wide mRNA and miRNA expression profiling reveal multiple regulatory networks in colorectal cancer.
    Vishnubalaji R; Hamam R; Abdulla MH; Mohammed MA; Kassem M; Al-Obeed O; Aldahmash A; Alajez NM
    Cell Death Dis; 2015 Jan; 6(1):e1614. PubMed ID: 25611389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical significance of expression of enhancer of zeste homolog 2 and 53 in cervical squamous cell carcinoma and intraepithelial neoplasia].
    Zhang H; Chen S; Niu G; Jiang H; Yao S
    Zhonghua Zhong Liu Za Zhi; 2014 Aug; 36(8):597-601. PubMed ID: 25430026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer.
    Liu Q; Wang G; Li Q; Jiang W; Kim JS; Wang R; Zhu S; Wang X; Yan L; Yi Y; Zhang L; Meng Q; Li C; Zhao D; Qiao Y; Li Y; Gursel DB; Chinnaiyan AM; Chen K; Cao Q
    Int J Cancer; 2019 Jul; 145(2):415-426. PubMed ID: 30628724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between mitochondrial TRAP-1 expression and lymph node metastasis in colorectal cancer.
    Gao JY; Song BR; Peng JJ; Lu YM
    World J Gastroenterol; 2012 Nov; 18(41):5965-71. PubMed ID: 23139614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Point mutations in the WD40 domain of Eed block its interaction with Ezh2.
    Denisenko O; Shnyreva M; Suzuki H; Bomsztyk K
    Mol Cell Biol; 1998 Oct; 18(10):5634-42. PubMed ID: 9742080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.
    Fornaro L; Faviana P; De Gregorio V; Vivaldi C; Paolicchi E; Masi G; Loupakis F; Sensi E; Lupi C; Fontanini G; Wang Y; Danesi R; Falcone A; Crea F
    BMC Cancer; 2015 Nov; 15():874. PubMed ID: 26553291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
    Behrens C; Solis LM; Lin H; Yuan P; Tang X; Kadara H; Riquelme E; Galindo H; Moran CA; Kalhor N; Swisher SG; Simon GR; Stewart DJ; Lee JJ; Wistuba II
    Clin Cancer Res; 2013 Dec; 19(23):6556-65. PubMed ID: 24097870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth.
    Hwang CF; Huang HY; Chen CH; Chien CY; Hsu YC; Li CF; Fang FM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):597-604. PubMed ID: 21300475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.